89bio, Inc. ETNB
Institutional shares held
89.1 Million
584K
calls
1.17M
puts
Total value of holdings
$714M
$4.68M
calls
$9.4M
puts
Market Cap
$372M
46,484,500
Shares Out.
Institutional ownership
191.64%
# of Institutions
164
We take great care to ensure that the data presented and summarized in this overview for 89bio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ETNB
View all-
Janus Henderson Group PLC London, X012.6MShares$101 Million0.08% of portfolio
-
Rtw Investments, LP New York, NY7.38MShares$59.1 Million1.38% of portfolio
-
Black Rock Inc. New York, NY6.64MShares$53.2 Million0.0% of portfolio
-
Suvretta Capital Management, LLC New York, NY6.3MShares$50.4 Million3.14% of portfolio
-
State Street Corp Boston, MA5.54MShares$44.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.72MShares$37.8 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA4.05MShares$32.4 Million1.41% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V83.71MShares$29.7 Million0.05% of portfolio
-
Pictet Asset Management Sa Geneva 73, V83.58MShares$28.6 Million0.08% of portfolio
-
Holocene Advisors, LP New York, NY3.45MShares$27.6 Million0.15% of portfolio
Latest Institutional Activity in ETNB
Top Purchases
Top Sells
About ETNB
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Insider Transactions at ETNB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 11
2024
|
Ra Capital Management, L.P. |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
1,408,450
+9.24%
|
$7,042,250
$5.33 P/Share
|
|
Apr 01
2024
|
Rohan Palekar Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
52,718
-10.3%
|
$527,180
$10.91 P/Share
|
|
Apr 01
2024
|
Rohan Palekar Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+4.66%
|
$25,000
$1.93 P/Share
|
|
Mar 04
2024
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,350,000
+9.8%
|
$20,250,000
$15.35 P/Share
|
|
Feb 26
2024
|
Rohan Palekar Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,477
-0.91%
|
$44,770
$10.76 P/Share
|
|
Feb 17
2024
|
Ryan Martins Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
778
-0.72%
|
$7,002
$9.74 P/Share
|
|
Feb 17
2024
|
Quoc Le Nguyen |
SELL
Payment of exercise price or tax liability
|
Direct |
1,046
-0.47%
|
$9,414
$9.74 P/Share
|
|
Feb 17
2024
|
Rohan Palekar Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,602
-0.93%
|
$41,418
$9.74 P/Share
|
|
Feb 17
2024
|
Harry H Mansbach Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,046
-0.66%
|
$9,414
$9.74 P/Share
|
|
Feb 09
2024
|
Ryan Martins Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,568
-3.22%
|
$28,544
$8.45 P/Share
|
|
Feb 09
2024
|
Quoc Le Nguyen |
SELL
Payment of exercise price or tax liability
|
Direct |
3,568
-1.57%
|
$28,544
$8.45 P/Share
|
|
Feb 09
2024
|
Harry H Mansbach Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,568
-2.19%
|
$28,544
$8.45 P/Share
|
|
Feb 09
2024
|
Rohan Palekar Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,670
-2.57%
|
$101,360
$8.45 P/Share
|
|
Feb 05
2024
|
Quoc Le Nguyen |
SELL
Payment of exercise price or tax liability
|
Direct |
1,190
-0.52%
|
$10,710
$9.8 P/Share
|
|
Feb 05
2024
|
Harry H Mansbach Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,190
-0.72%
|
$10,710
$9.8 P/Share
|
|
Feb 05
2024
|
Rohan Palekar Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,068
-1.02%
|
$45,612
$9.8 P/Share
|
|
Feb 05
2024
|
Ryan Martins Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
892
-0.8%
|
$8,028
$9.8 P/Share
|
|
Feb 01
2024
|
Quoc Le Nguyen |
BUY
Grant, award, or other acquisition
|
Direct |
48,750
+17.62%
|
-
|
|
Feb 01
2024
|
Harry H Mansbach Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
48,750
+22.89%
|
-
|
|
Feb 01
2024
|
Rohan Palekar Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+23.12%
|
-
|
Last 12 Months Summary
Buy / Acquisition
3.34M
Shares
From
8
Insiders
| Open market or private purchase | 1.35M shares |
|---|---|
| Exercise of in-the-money or at-the-money derivatives securities | 1.41M shares |
| Grant, award, or other acquisition | 492K shares |
| Exercise of conversion of derivative security | 87.5K shares |
Sell / Disposition
256K
Shares
From
6
Insiders
| Payment of exercise price or tax liability | 136K shares |
|---|---|
| Open market or private sale | 120K shares |